Inotersen Sodium Patent Expiration
Inotersen Sodium is Used for treating polyneuropathy in individuals with hereditary transthyretin amyloidosis. It was first introduced by Akcea Therapeutics Inc
Inotersen Sodium Patents
Given below is the list of patents protecting Inotersen Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tegsedi | US7015315 | Gapped oligonucleotides |
Mar 21, 2023
(Expired) | Akcea Theraps |
| Tegsedi | US7101993 | Oligonucleotides containing 2′-O-modified purines |
Sep 05, 2023
(Expired) | Akcea Theraps |
| Tegsedi | US8101743 | Modulation of transthyretin expression | Apr 01, 2025 | Akcea Theraps |
| Tegsedi | US8697860 | Diagnosis and treatment of disease | Apr 29, 2031 | Akcea Theraps |
| Tegsedi | US9061044 | Modulation of transthyretin expression | Apr 29, 2031 | Akcea Theraps |
| Tegsedi | US9399774 | Modulation of transthyretin expression | Apr 29, 2031 | Akcea Theraps |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Inotersen Sodium's patents.
Latest Legal Activities on Inotersen Sodium's Patents
Given below is the list recent legal activities going on the following patents of Inotersen Sodium.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Patent Term Extension Application under 35 USC 156 Filed | 16 Feb, 2024 | US8101743 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jan, 2024 | US9399774 |
| FDA Final Eligibility Letter | 14 Nov, 2023 | US8101743 |
| FDA Final Eligibility Letter | 14 Nov, 2023 | US9061044 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Jul, 2023 | US8101743 |
| transaction for FDA Determination of Regulatory Review Period | 28 Mar, 2023 | US9061044 |
| transaction for FDA Determination of Regulatory Review Period | 28 Mar, 2023 | US8101743 |
| transaction for FDA Determination of Regulatory Review Period | 28 Mar, 2023 | US9399774 |
| transaction for FDA Determination of Regulatory Review Period | 23 Mar, 2023 | US9061044 |
| transaction for FDA Determination of Regulatory Review Period | 23 Mar, 2023 | US9399774 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳